Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 16/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17631222 | 0.84 | GPR119 (0.43) | TBK1GPR119 | |
| SCHEMBL17631219 | 0.84 | GPR119 (0.43) | TBK1GPR119 | |
| SCHEMBL17631162 | 0.75 | TBK1 (0.42) | TBK1GPR119JAK2PDE4B | |
| SCHEMBL17645231 | 0.75 | TBK1 (0.42) | TBK1GPR119JAK2PDE4B | |
| SCHEMBL17630657 | 0.75 | TBK1 (0.40) | TBK1JAK2 | |
| SCHEMBL17630496 | 0.73 | TBK1 (0.40) | TBK1JAK2 | |
| SCHEMBL25243028 | 0.70 | PDE4B (0.46) | GPR119PDE4B | |
| SCHEMBL4453817 | 0.69 | CCNB2 (0.40) | — | |
| SCHEMBL30075766 | 0.69 | LMNA (0.44) | PDE4B | |
| SCHEMBL30075785 | 0.69 | LMNA (0.44) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197884-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049211-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-03-31 | — | — | WO | disclosed |